1403 results about "Liver function" patented technology

The present invention relates to a diagnostic agent for liver function, comprising a compound labelled with 13C at least at one specific position selected from the group consisting of the following (a) to (f): (a) galactose, glucose or xylose labelled with 13C at least at one specific position or a starch composed of glucose units labelled with 13C at least at one specific position; (b) a polar amino acid, heterocyclic amino acid, isoleucine or valine labelled with 13C at least at one specific position; (c) a carboxylic acid constituting the glycolytic pathway or the citric acid cycle, labelled with 13C at least at one specific position; (d) a fatty acid labelled with 13C at least at one specific position; (e) a glyceride labelled with 13C at least at one specific position; and (f) glycerol labelled with 13C at least at one specific position. According to the present invention, a diagnostic agent for liver function which imposes less physical burden on a subject, can give accurate test result immediately, and can be used safely without side effects is provided. The diagnostic agent of the invention is useful for evaluating the liver function of a subject at the time when the test is carried out.

A method for cultivating Antrodia Camphorata is provided. First, Antrodia Camphorata is pre-incubated on a sloped surface culture medium. A portion of the pre-incubated Antrodia Camphorata is transferred to a liquid culture medium for incubation. Then, Antrodia Camphorata incubated in the liquid culture medium is moved to a solid culture medium for incubation. The cultivated Antrodia Camphorata has similar efficacies for inhibiting cancel cell growth, reducing the occurrence of atherosclerosis or recovering the damaged liver functions, as the wild Antrodia Camphorata.

The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia. The present invention further relates to methods for inducing the regeneration of cells, tissues, organs and organic systems such as the circulatory, nervous and endocrine systems. Finally, the present invention relates to methods for restoring immune response in an animal, in particular a human being.

Performing image diagnosis in an easier and more appropriate manner by focusing on functional levels and segments of a liver. A segment function level calculation unit obtains, from liver function angiographic images obtained using a contrast agent that produces a contrast effect according to a functional level of a liver of diagnostic target, evaluation values representing functional levels of a plurality of liver segments in liver regions, a display image generation unit generates an image based on the evaluation values, and the image so generated is displayed on a display unit.

Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and/or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.

The present invention relates to 5-thia-omega-substituted phenylprostaglandin E derivatives of the formula (I)(wherein, all the symbols are as defined in the specification), process for producing them and pharmaceutical compositions comprising them as active ingredient.The compounds of the formula (I) can bind to PGE2 receptors (especially, subtype EP4) strongly, so they are expected to be useful for prevention and/or treatment of immunological diseases (autoimmune diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjoegren's syndrome, chronic rheumarthrosis and systemic lupus erythematosus etc., and rejection after organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia, systemic inflammatory response syndrome, ambustion pain, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, and shock etc. Further, it is thought that EP4 subtype receptor relates to sleeping disorder and blood platelet aggregation, so the compounds of the present invention are expected to be useful for the prevention and/or treatment of such diseases.

Engineered, living, three-dimensional liver tissue constructs comprising: one or more layers, wherein each layer contains one or more liver cell types, the one or more layers cohered to form a living, three-dimensional liver tissue construct. In some embodiments, the constructs are characterized by having at least one of: at least one layer comprising a plurality of cell types, the cell types spatially arranged relative to each other to create a planar geometry; and a plurality of layers, at least one layer compositionally or architecturally distinct from at least one other layer to create a laminar geometry. Also disclosed are arrays and methods of making the same. Also disclosed are engineered, living, three-dimensional liver tissue constructs for use in the augmentation or restoration of one or more liver functions, by in vivo delivery of tissue or utilization of tissue in an extracorporeal device.

The present invention relates to multipotent stem cells derived from the interstitial tissues of skeletal muscle. The multipotent stem cell of the present invention is capable of differentiating into skeletal muscle cells, smooth muscle cells, cardiomyocytes, blood cells, vascular endothelial cells, adipocytes, osteoblasts, nervous cells, hepatocytes and pancreatic cells, and is useful for regeneration of tissues and cells and treatment for cardiac failure, hepatic insufficiency, renal insufficiency, leukemia, nerve degeneration disease, arthritis, diabetes, arteriosclerosis, and the like.

This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent.

The invention relates to a method for establishing a Gadd45a knockout rabbit model by adopting a knockout technology and belongs to the technical field of biotechnology. The invention aims to establish a rabbit model by knocking out GADD45a gene by utilizing a Grispr/cas9 technology and to provide the method for establishing the Gadd45a knockout rabbit model by adopting the knockout technology andfor researching the influence of the gene on animal liver. The method provided by the invention comprises the following steps: establishing sgRNA; synthesizing double-stranded DNA; linearizing p UC-57 carrier; linking p UC-57 carrier with double-stranded DNA; converting; performing monoclonal picking and plasmid DNA extraction; identifying plasmid sequence; expressing plasmid with CAS9; and performing digestion linearization for in vitro transcription. Through related detection, the invention successfully acquires the Gadd45a knockout rabbit model; the model is established for simulating theclinic pathological processes of the liver diseases, such as, fatty liver, liver cirrhosis and liver cancer after giving the corresponding alcohol stimulation, is capable of effectively forecasting the clinic application effects of new vaccine, new drugs and new diagnostic reagents, and meanwhile, and is capable of greatly reducing the risk in researching and developing the new drugs; and a basismodel is supplied for the clinical research.

A Chinese medicine for preventing and treating cholecystitis, cholelithiasis and the inflammation of biliary tract, and improving the function of gallbladder and liver is prepared from 23 Chinese-medicinal materials including tackahoe, capejasmine fruit, white peony root, cyprus tuber, etc.

The invention provides a product having sobering up and liver protecting functions and its preparation method and use, which comprises the following raw material (by weight ratio), soybean peptides and soybean extract 2.5-12:0.5, panaxoside or ginkgo leaf extract, green tea polyphenols, glutacid, arginine or lycine, vitamin C, vitamin B6, vitamin B1, vitamin B2 or vitamin B12. The medicament can be made into various dose forms including capsule, oral liquid, tablet, effervescent tablet or injection.

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition comprises a multiparticulate modified release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules as the primary package. The oral dosage units are supplied as part of a kit, which also includes a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment.

The invention relates to a preparation method of a xylitol liver-protecting tablet, belonging to the technical field of medical health care. The formula of the xylitol liver-protecting tablet comprises the following raw materials in proportion: 15-45 parts of kudzu root extract, 2-20 parts of glycyrrhizic acid, 5-35 parts of propolis powder, 20-60 parts of xylitol, 1-10 parts of low-substituted hydroxypropyl cellulose, 1-10 parts of cross-linked sodium carboxymethyl cellulose and 0.5-5 parts of magnesium stearate; and a coating agent comprises 0.5-40 parts of hydroxypropyl methylcellulose, 1-30 parts of polyethylene glycol 6000, 0.5-40 parts of talcum powder, 0.5-30 parts of titanium pigment, 0.5-30 parts of iron oxide brown and 10-75 parts of maltitol. The finished product of the xylitol liver-protecting tablet is prepared by the processing steps of crushing, mixing, tabletting, coating and the like. In the invention, by using the xylitol as a main raw material and adding partial auxiliary materials, the xylitol liver-protecting tablet which is a health food and has auxiliary protection effect on chemical liver injury is prepared. The xylitol liver-protecting tablet can effectively prevent and treat fatty liver; and after patients suffering from the fatty liver take the xylitol liver-protecting tablet, severe fatty liver can be relieved into moderate fatty liver, and moderate fatty liver can be relieved into mild fatty liver. Thus, the xylitol liver-protecting tablet has obvious benefit to improve liver functions of human bodies and has wide market prospects.

The invention relates to a drink, in particular to a chrysanthemum health drink strengthening immunity of organisms and suitable to be drunk by various groups, and a preparation method thereof. The honeysuckle health drink is prepared from the following raw materials in portion by weight: chrysanthemum, Chinese wolfberry, honey, citric acid and water of which the ratio is 10-30:5-15:25-45:0.1-1.0:200-400. The chrysanthemum health drink has scientific formula, simple preparation process, good color, aroma and taste, and rich nutrient and is suitable to be drunk by various groups for a long time; the chrysanthemum is adopted as a main raw material, can make people have clear head and bright eyes, and particularly has good treatment effect on excitable computer group with dry eyes caused by eye strain; and the chrysanthemum health drink also has the effects of improving liver function, clearing heat and releasing toxicity, resisting bacteria and diminishing inflammation, strengthening theimmunity and the like, and makes up for the deficiency that carbonated beverage, water, tea, milk and juice beverage only exist in the market but dietetic beverage is absent.

The invention discloses an abnormal fasting blood glucose level early-warning method based on an integrated learning fusion model. With combination of individual physical examination data of blood routine examination, liver function, blood fat, and renal function and the like, a fasting blood glucose level is predicted by fusing a gradient regression tree, a random forest, and a linear regressionmodel and the like based on an integrated learning method. The prediction model is trained by using lots of training data, so that the accuracy, universality and robustness of the prediction model areimproved. Fasting blood glucose level prediction is carried out on timely an individual without fasting blood glucose checking, so that the high-diabetes-risk patient is warned early and effectively.

The present invention provides methods for treating alphavirus infections; methods of treating hepatitis C virus (HCV) infections; methods of treating West Nile virus infection; methods of reducing liver fibrosis; methods of increasing liver function in an individual suffering from liver fibrosis; methods of reducing the incidence of complications associated with HCV and cirrhosis of the liver; and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from viral infection. The methods generally involve administering effective amounts of an interferon receptor agonist and pirfenidone in combination therapy.

The present invention relates to one kind of plant leavening prepared by using plant with hot and fragrant smell of propylene sulfide, yeast and lactobacillus and through fermentation. The present invention also relates to the preparation process of the leavening and its application is treating presbyopia, cataract and other diseases, promoting blood circulation; improving the functions of sexual organs, kidney, cardiac and cerebral vascular system, digestive system, etc.; resisting oxidation, senility and fatigue; lowering blood fat, blood sugar and blood pressure; etc.

A system, method and apparatus are disclosed for using a transcutaneous detection system to measure the quantity of a circulating organ activity detection analyte in the blood, and thereby assay the activity of an organ. A preferred organ for assay is the human liver and a preferred indicator is indocyanine green (ICG) dye The procedure is under the control of a monitor/controller having a visual display and capable of providing cues to the operator. A sensor array apparatus for use in conjunction with the system monitor/controller is configured for increased sensitivity of assaying organ function.

The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.

The invention discloses a Chinese pharmaceutical composition for treating hepatitis and fatty liver, which comprises cornus officinalis, oriental wormwood, cape jasmine, baikal skullcap root, plantain seeds, clematis stem, polyporus umbellatus, poria cocos, rush pith, curcuma aromatica, licorice root, cyperus tuber, dandelion, white atractylodes rhizome, magnolia bark, Bupleurum root, chicken's gizzard-skin, green tangerine orange peel, banksia rose, malt, isatic root, haw, turtle shell, burred tuber, Loranthus mulberry mistletoe, talcum powder, bitter orange, zedoary, fleece-flower root, root of herbaceous peony, medicated leaven, Chinese angelica root, rhubarb horsetails.